Clinical Trials Sponsored by BCB Medical

Total 56715 results

UCB Pharma

Completed

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

Epilepsy

United States, Poland, Mexico, Russian Federation
UCB Pharma

Completed

Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis

Allergic Rhinitis
UCB Pharma

Completed

Wheal and Flare Reaction During 24 Hours in Allergic Volunteers.

Allergy

France
UCB Pharma

Completed

Evaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine

Allergies

United States
UCB Pharma

Completed

Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites

Rhinitis | Allergic | Perennial
UCB Pharma

Completed

Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive Subjects

Rhinitis, Allergic, Seasonal
UCB Pharma

Completed

Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis

Rhinitis, Allergic, Seasonal
UCB Pharma

Completed

Safety and Tolerability of Levetiracetam Intravenous 15 Minute Infusion in Subjects Suffering From Partial Onset Seizures

Epilepsy
UCB Pharma

Completed

Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia

Dyskinesia, Medication-induced

Belgium, Bulgaria
UCB Pharma

Completed

Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias

Idiopathic Parkinson Disease
UCB Pharma

Completed

Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy

Epilepsy
UCB Pharma

Completed

Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)

Anxiety Disorders
UCB Pharma

Completed

A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)

Crohn's Disease
UCB Pharma

Completed

Bio-availability Comparison of Three Formulations of Certolizumab Pegol in Healthy Volunteers

Bioavailability Study on Healthy Volunteers

France
UCB Pharma

Completed

Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).

Crohn's Disease
UCB Pharma

Completed

A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease

Parkinson's Disease

United States
UCB Pharma

Completed

Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis

Rheumatoid Arthritis
UCB Pharma

Completed

A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis

Multiple Sclerosis

United States
UCB Pharma

Completed

A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety

ANXIETY

United States
Terumo BCT

Completed

Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure

Multiple Myeloma

United States
UCB Pharma

Completed

A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis

Diabetic Gastroparesis

United States
UCB Pharma

Terminated

Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States, France, United Kingdom, Spain, Belgium, Netherlands, Canada, Brazil, Germany, Czech Republic, Italy
UCB Pharma

Completed

Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy

Epilepsy

United States
UCB Pharma

Withdrawn

Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy

Epilepsy
UCB Pharma

Completed

Efficacy and Safety of Levetiracetam in Routine Clinical Practice in Czech and Slovak Republics, Hungary, and Romania.

Epilepsy
UCB Pharma

Completed

Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body

Healthy Volunteers

Germany
UCB Pharma

Completed

Effect of Lacosamide 200 mg Twice a Day (Bid) on Single Dose Warfarin 25 mg in Healthy Males

Healthy Volunteers

Netherlands
UCB Pharma

Withdrawn

Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.

Epilepsy
UCB Pharma

Completed

Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study (CERTAIN)

Rheumatoid Arthritis

France, Poland, Germany, Austria, Italy
UCB Pharma

Completed

To Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean Subjects

Epilepsy
UCB Pharma

Completed

Bioequivalence Study of Levetiracetam Tablet and Intravenous Infusion in Healthy Japanese Subjects

Healthy Volunteers

United Kingdom
UCB Pharma

Completed

Evaluation of the Effects of Certolizumab Pegol on Semen Quality in Healthy Male Volunteers

Sperm Quality

Belgium
UCB Pharma

Completed

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United States
UCB Pharma

Completed

Mucosal Healing Study in Crohn's Disease (CD) (MUSIC)

Crohn's Disease

France, Germany, Belgium
UCB Pharma

Terminated

Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab

Crohn's Disease

Greece
UCB Pharma

Completed

Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy

Epilepsy

France, United States, Belgium, Mexico, Turkey, Germany
UCB Pharma

Completed

Three-way-cross-over Study to Evaluate Safety and Pharmacokinetics of Lacosamide in Healthy Japanese and Chinese Males

Healthy Volunteers

Germany
UCB Pharma

Completed

Efficacy and Safety of Cetirizine Tablets Versus Ketotifen Dry Syrup in Children With Perennial Allergic Rhinitis

Rhinitis, Allergic, Perennial
Philipps University Marburg Medical Center
UCB Pharma GmbH

Completed

Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy

Epilepsy

Germany
University of Texas Southwestern Medical Center
UCB Pharma

Completed

Levetiracetam for Neuroprotection Against Corticosteroid-induced Hippocampal Dysfunction: A Proof of Concept Study

Memory Loss Associated With Corticosteroid Use | Manic State Associated With Corticosteroid Use

United States
UCB S.A. - Pharma Sector

Completed

Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

Epilepsy, Partial

United States
UCB Biopharma SRL
Parexel

Completed

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

Chronic Plaque Psoriasis

United States, Australia, Canada, Moldova, Republic of
UCB PHARMA Inc. (US)

Completed

This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

Epilepsy

United States, Australia, Brazil, Canada, India, Mexico
UCB BIOSCIENCES GmbH
Parexel

Completed

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo (C-OPTIMISE)

Ankylosing Spondylitis | Axial Spondyloarthrithis

United States, Belgium, Bulgaria, Czechia, France, Germany, Hungary, Netherlands, Poland, Romania, Spain, Taiwan, Turkey, United Kingdom
UCB Japan Co. Ltd.

Completed

A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures

Epilepsies | Partial

Japan
UCB Korea Co., Ltd.

Completed

Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

Idiopathic Parkinson's Disease

Korea, Republic of
Korea UCB Co., Ltd.

Completed

Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy (OPTIMAL)

Epilepsy

Korea, Republic of
UCB Japan Co. Ltd.

Completed

A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures

Epilepsies, Partial

Japan
UCB Japan Co. Ltd.

Completed

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Rheumatoid Arthritis

Japan, Korea, Republic of, Taiwan
UCB Pharma

Completed

A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).

Postherpetic Neuralgia

3

Subscribe